Oruka Therapeutics (NASDAQ:ORKA) Shares Gap Up – Here’s What Happened

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $72.34, but opened at $81.00. Oruka Therapeutics shares last traded at $82.4510, with a volume of 400,989 shares traded.

Analysts Set New Price Targets

ORKA has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, April 21st. Stifel Nicolaus raised their target price on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Barclays boosted their target price on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, April 27th. Leerink Partners set a $120.00 price target on Oruka Therapeutics in a research report on Thursday, April 30th. Finally, HC Wainwright restated a “buy” rating and issued a $120.00 price target on shares of Oruka Therapeutics in a research report on Tuesday. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.30.

Oruka Therapeutics Trading Down 2.3%

The firm has a fifty day moving average price of $65.64 and a 200 day moving average price of $46.27. The firm has a market cap of $5.03 billion, a PE ratio of -42.99 and a beta of -0.26.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. As a group, equities analysts predict that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current year.

Insider Activity

In other news, SVP Arjun Agarwal sold 10,290 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $59.07, for a total value of $607,830.30. Following the completion of the sale, the senior vice president owned 16,406 shares of the company’s stock, valued at $969,102.42. This represents a 38.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $69.69, for a total transaction of $120,494.01. Following the sale, the chief executive officer owned 925,580 shares of the company’s stock, valued at $64,503,670.20. This represents a 0.19% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 185,407 shares of company stock valued at $11,636,307. Company insiders own 23.49% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ORKA. Avidity Partners Management LP increased its stake in Oruka Therapeutics by 15.1% during the first quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock worth $37,299,000 after acquiring an additional 100,000 shares during the last quarter. Glenmede Trust Co. NA lifted its stake in shares of Oruka Therapeutics by 11.7% in the 1st quarter. Glenmede Trust Co. NA now owns 21,772 shares of the company’s stock valued at $1,068,000 after purchasing an additional 2,287 shares during the last quarter. Remedium Capital Partners LLC lifted its stake in shares of Oruka Therapeutics by 0.9% in the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock valued at $76,796,000 after purchasing an additional 13,247 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Oruka Therapeutics by 178.5% during the 1st quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock worth $155,000 after purchasing an additional 2,033 shares during the period. Finally, Rock Springs Capital Management LP purchased a new position in shares of Oruka Therapeutics during the 1st quarter worth $202,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.